CARsgen Therapeutics Holdings Ltd.
10.82
HKD
-1.18
(-9.83%)
ISIN
KYG1996C1006
CUSIP
G1996C100
Return %
Stock
S&P 500
1Y
-35.79
14.20
3Y
16.97
81.12
5Y
-74.63
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zong Hai Li
- Full Time Employees
- 362
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building 12 Shanghai SH China 200231
- IPO Date
- Jun 18, 2021
- Website
- carsgen.com
- Similar Companies
- Business
- CARsgen Therapeutics Holdings Limited (2171.HK) is a biopharmaceutical company that discovers, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies, solid tumors and autoimmune diseases. The company maintains an integrated cell therapy platform encompassing target discovery, antibody development, preclinical research, clinical trials and commercial-scale manufacturing with proprietary technologies including THANK-uCAR for allogeneic CAR-T cells, CARcelerate for rapid production, CycloCAR to enhance solid tumor efficacy and LADAR for precise targeting. Core products comprise the fully human autologous BCMA CAR-T therapy zevor-cel (CT053, zevorcabtagene autoleucel), approved by China's NMPA in February 2024 for relapsed/refractory multiple myeloma after at least three prior lines of therapy; satri-cel (CT041, satricabtagene autoleucel), the first Claudin18.2-targeted CAR-T for solid tumors with NDA accepted by NMPA under priority review and breakthrough therapy designation for advanced gastric/gastroesophageal junction adenocarcinoma; CT071, a GPRC5D-targeted CAR-T using CARcelerate platform; CT011, a glypican-3-targeted CAR-T for hepatocellular carcinoma; and allogeneic candidates CT0590 (BCMA/NKG2A-targeted), CT0596 (BCMA-targeted with positive clinical data in multiple myeloma and plasma cell leukemia), KJ-C2219, KJ-C2320, KJ-C2114 and KJ-C2526 targeting various hematological and solid tumors. Operations span China and the United States with GMP facilities in Shanghai, Jinshan, RTP North Carolina and Bellaire Texas; founded in 2014, CARsgen is headquartered at 1F Building 2 No 466 Yindu Road Xuhui District Shanghai China. Recent developments include a February 2025 strategic partnership with Zhuhai Hengqin SB Xinchuang via its managed fund subscribing RMB80 million for 8% equity in subsidiary UCARsgen Biotech to accelerate allogeneic CAR-T commercialization in mainland China; NMPA priority approval in November 2025 of Claudin18.2 companion diagnostic kit for satri-cel; positive November 2025 clinical data for allogeneic CAR-T products CT0596 and CT1190B; October 2025 premarket approval application acceptance for the companion diagnostic; September 2025 long-term follow-up results for zevor-cel; and October 2025 preliminary satri-cel data in pancreatic cancer adjuvant therapy at ESMO Congress. Commercial rights for zevor-cel in mainland China rest with Huadong Medicine and in South Korea with HK Inno.N.
Company News
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit